Related Experiment Video
Updated: Aug 4, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Hypertensive crisis: diagnosis, presentation, and treatment
1Department of Cardiology, Ochsner Heart & Vascular Institute.
Insights
Hypertensive crisis (HTN-C) management is evolving, with new markers for early damage detection. Research explores lower blood pressure targets in specific scenarios, guiding tailored therapeutic agent selection for better outcomes.
Area of Science:
- Cardiology
- Nephrology
- Neurology
Background:
- Hypertensive crisis (HTN-C) is increasingly prevalent, associated with significant morbidity and mortality.
- Prompt recognition and treatment of HTN-C are critical for patient outcomes.
- Limited controlled trials necessitate a review of current literature for effective HTN-C management.
Approach:
- Review of novel serological markers for early end-organ damage detection.
- Analysis of blood pressure targets in ischemic stroke following thrombolysis and mechanical thrombectomy.
- Evaluation of antihypertensive agents, including clevidipine and oral nifedipine, for specific clinical scenarios.
Key Points:
- Serum corin aids in early identification of end-organ damage in severe hypertension.
- Lower blood pressure targets (130-140 mmHg) show some benefit post-ischemic stroke thrombolysis.
- Clevidipine is noninferior to nicardipine for HTN-C; oral nifedipine is effective in preeclampsia.
Conclusions:
- Hypertensive crisis management lacks extensive prospective trials but is an active research area.
- Identifying lower blood pressure goals for specific clinical scenarios is ongoing.
- Tailoring therapeutic agents to specific end-organ damage is essential for optimal HTN-C treatment.
Purpose Of Review:
Hypertensive crisis (HTN-C) is a condition of increasing prevalence. It carries significant morbidity and mortality, and prompt recognition and treatment are crucial. There is a paucity of controlled trials, so a working knowledge of the most recent literature in the area of HTN-C is helpful.
Recent Findings:
Novel serological markers, including serum corin, have been found to aid in the early identification of end-organ damage from severely elevated blood pressure (BP). In the area of BP following thrombolysis for ischemic stroke, lower target BP (130-140 mmHg) is associated with some improved outcomes. Two large trials of lower BP following mechanical thrombectomy in stroke have failed to show improved outcomes; however, observed data show benefits at lower than currently recommended levels. Clevidipine, a calcium channel blocker marketed for unique use in HTN-C, was found to be noninferior to the generic less expensive nicardipine. Oral nifedipine was found to be the most effective agent for sustained BP reduction in preeclampsia.
Summary:
HTN-C remains an area with few prospective randomized trials, but there is active research on identifying lower goals for specific clinical scenarios. Ideal therapeutic agents should be tailored for specific end-organ damage.
More Related Videos
Related Concept Videos
Hypertension I: Introduction
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management
Hypertension IV: Drug Therapy and Lifestyle Modifications
Acute Coronary Syndrome V: Nursing Management
Hypertension II: Pathophysiology

